eBook - ePub
Significant Pharmaceuticals Reported in US Patents
Thomas F. DeRosa
This is a test
Condividi libro
- 700 pagine
- English
- ePUB (disponibile sull'app)
- Disponibile su iOS e Android
eBook - ePub
Significant Pharmaceuticals Reported in US Patents
Thomas F. DeRosa
Dettagli del libro
Anteprima del libro
Indice dei contenuti
Citazioni
Informazioni sul libro
Significant Pharmaceuticals Reported in US Patents identifies the next generation of pharmaceuticals reported in US Patents. This "hands-on" title provides explicit laboratory methods for preparing the most recent and effective medications. Each entry documents the biological testing protocols used to evaluate a drug and the significance of the current treatment agent over previous methods. Pharmaceuticals are included in this review only if at least two of the following criteria were met: Effectiveness in treating an illness, Innovative, ease of preparation, synergy with existing Medications.
Pharmaceuticals are reported for 27 separate classes of illness, including: AIDS, Alzheimer's Disease, Cardiovascular Disorders, Diabetes, Epilepsy, Hepatitis C, Osteoporosis, Obesity and Sleep Disorders.
Significant Pharmaceuticals Reported in US Patents has been designed to be used as both a reference and synthetic guide for pharmaceutical, medicinal and organic chemists and graduate students.
Researchers working in other areas will also find the information valuable as in many instances intermediates or the next generation pharmaceutical are readily convertible into other industrial products including: anti-oxidants, chemical additives, herbicides, polymer precursors, water purification agents. Clear structural depictions of reagents and chemical transformations have been supplied to permit the identification of other future applications.
- Identifies next generation pharmaceuticals
- Provides practical preparation methods for each active agent and derivatives
- Documents the analytical characterization and biological testing results of active agents
Domande frequenti
Come faccio ad annullare l'abbonamento?
È semplicissimo: basta accedere alla sezione Account nelle Impostazioni e cliccare su "Annulla abbonamento". Dopo la cancellazione, l'abbonamento rimarrà attivo per il periodo rimanente già pagato. Per maggiori informazioni, clicca qui
È possibile scaricare libri? Se sì, come?
Al momento è possibile scaricare tramite l'app tutti i nostri libri ePub mobile-friendly. Anche la maggior parte dei nostri PDF è scaricabile e stiamo lavorando per rendere disponibile quanto prima il download di tutti gli altri file. Per maggiori informazioni, clicca qui
Che differenza c'è tra i piani?
Entrambi i piani ti danno accesso illimitato alla libreria e a tutte le funzionalità di Perlego. Le uniche differenze sono il prezzo e il periodo di abbonamento: con il piano annuale risparmierai circa il 30% rispetto a 12 rate con quello mensile.
Cos'è Perlego?
Perlego è un servizio di abbonamento a testi accademici, che ti permette di accedere a un'intera libreria online a un prezzo inferiore rispetto a quello che pagheresti per acquistare un singolo libro al mese. Con oltre 1 milione di testi suddivisi in più di 1.000 categorie, troverai sicuramente ciò che fa per te! Per maggiori informazioni, clicca qui.
Perlego supporta la sintesi vocale?
Cerca l'icona Sintesi vocale nel prossimo libro che leggerai per verificare se è possibile riprodurre l'audio. Questo strumento permette di leggere il testo a voce alta, evidenziandolo man mano che la lettura procede. Puoi aumentare o diminuire la velocità della sintesi vocale, oppure sospendere la riproduzione. Per maggiori informazioni, clicca qui.
Significant Pharmaceuticals Reported in US Patents è disponibile online in formato PDF/ePub?
Sì, puoi accedere a Significant Pharmaceuticals Reported in US Patents di Thomas F. DeRosa in formato PDF e/o ePub, così come ad altri libri molto apprezzati nelle sezioni relative a Physical Sciences e Analytic Chemistry. Scopri oltre 1 milione di libri disponibili nel nostro catalogo.
Informazioni
Argomento
Physical SciencesCategoria
Analytic ChemistryChapter I
Acquired Immune Deficiency Syndrome
I Antioxidants, Preparation Methods, and Uses
Title Antioxidants, Preparation Methods and Uses
J. Oiry et al., US Patent 6,989,372 (January 24, 2006)
J. Oiry et al., US Patent 6,989,372 (January 24, 2006)
Assignee Centre National de la Recherche Scientifique and Commissariat a l'Engergie Atomique
Utility Treatment of Pathologies Associated with Glutathione Depletion
Invention Significance Reactive oxygen species play an important role in human pathologies and are particularly associated with retroviral infections such as human immunodeficiency virus (HIV). Intracellular defense against oxidative species is controlled by glutathione. To contain these reactive oxygen species effects, free radical scavengers have been prepared that increase glutathione reserves.
Reaction
i- N-Methylmorpholine, isobutyl chloroformate, EtOAc, S-acetylcysteamine · HCl
ii- Methyl alcohol, CHCl3, silver nitrate, pyridine
iii- CHCl3, hydrochloric acid
Experimental
1. Preparation of N-(N-acetyl-S-trityl-l-cysteinyl)-S-acetylcysteamine
A solution of N-acetyl-S-trityl-l-cysteine (0.71 mmol) and 80μ1 N-methylmorpholine dissolved in 5 ml of EtOAc was stirred at–15°C, then treated with 93μl isobutyl chloroformate. After 15 minutes, S-acetylcysteamine hydrochloride (0.71 mmol) and an additional 80μl N-methyl-morpholine were added and the mixture stirred for 15 minutes at – 15°C and then 3 hours at ambient temperature. N-Methylmorpholine hydrochloride was then filtered off and the mixture was washed twice with 2.5 ml of EtOAc and concentrated. The gummy residue was purified by flash chromatography with silica gel using EtOAc/30% petroleum ether and the product isolated in 55% yield as a colorless powder, mp=111−113°C.
Rf = 0.41, EtOAc/petroleum ether, 9:1
[α]D20=+10.5° (c. 0.8, CHCl3
1H NMR (CDCl3) δ (ppm) 1.90 (s, 3H, NCOCH3), 2.29 (s, 3H, SCOCH3), 2.48 (dd, J = 5.7, 12.9Hz, 1H, β Ha cys), 2.82 (dd, J = 6.4, 12.9Hz, 1H, β Hb cys), 2.92–3.01 (m, 2H, NCH2CH2S), 3.32–3.42 (m, 2H, NCH2CH2S), 4.07–4.20 (m, 1H, α H cys), 5.70 (d, J = 7.6Hz, 1H, NH cys), 6.34 (t, J = 5.5Hz, 1H, NHCH2), 7.19–7.35 and 7.40–7.47 (2m, 15H, aromatic H)
MS (FAB +/NBA + K +) m/z 545 (M + K)+, 507 (M + H)+; (FAB-/NRA) m/z 505 (M-H)−
Analysis Calc. for C28H30N2O3S2 (506): C, 66.40; H, 5.93; N, 5.53. Found: C, 66.17; H, 6.00; N, 5.81
A solution of N-acetyl-S-trityl-l-cysteine (0.71 mmol) and 80μ1 N-methylmorpholine dissolved in 5 ml of EtOAc was stirred at–15°C, then treated with 93μl isobutyl chloroformate. After 15 minutes, S-acetylcysteamine hydrochloride (0.71 mmol) and an additional 80μl N-methyl-morpholine were added and the mixture stirred for 15 minutes at – 15°C and then 3 hours at ambient temperature. N-Methylmorpholine hydrochloride was then filtered off and the mixture was washed twice with 2.5 ml of EtOAc and concentrated. The gummy residue was purified by flash chromatography with silica gel using EtOAc/30% petroleum ether and the product isolated in 55% yield as a colorless powder, mp=111−113°C.
Rf = 0.41, EtOAc/petroleum ether, 9:1
[α]D20=+10.5° (c. 0.8, CHCl3
1H NMR (CDCl3) δ (ppm) 1.90 (s, 3H, NCOCH3), 2.29 (s, 3H, SCOCH3), 2.48 (dd, J = 5.7, 12.9Hz, 1H, β Ha cys), 2.82 (dd, J = 6.4, 12.9Hz, 1H, β Hb cys), 2.92–3.01 (m, 2H, NCH2CH2S), 3.32–3.42 (m, 2H, NCH2CH2S), 4.07–4.20 (m, 1H, α H cys), 5.70 (d, J = 7.6Hz, 1H, NH cys), 6.34 (t, J = 5.5Hz, 1H, NHCH2), 7.19–7.35 and 7.40–7.47 (2m, 15H, aromatic H)
MS (FAB +/NBA + K +) m/z 545 (M + K)+, 507 (M + H)+; (FAB-/NRA) m/z 505 (M-H)−
Analysis Calc. for C28H30N2O3S2 (506): C, 66.40; H, 5.93; N, 5.53. Found: C, 66.17; H, 6.00; N, 5.81
2...